Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
TUSSIONEX PENNKINETIC is an extended-release oral suspension combining hydrocodone (semisynthetic opioid antitussive) and chlorpheniramine (antihistamine) for cough suppression. Hydrocodone acts directly on the cough center while chlorpheniramine prevents histamine-induced respiratory mucosa edema. The Pennkinetic delivery system provides controlled, prolonged release over an extended dosing interval.
As LOE approaches, the brand team is likely in defensive mode with focus on retention programs and cost optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TUSSIONEX PENNKINETIC offers limited growth trajectory but provides valuable experience in mature product management, opioid regulatory compliance, and defensive commercial strategy. This role is best suited for professionals building expertise in LOE management and transitioning portfolios rather than high-growth product launches.
Worked on TUSSIONEX PENNKINETIC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.